mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for CAMKK2
Gene summary
Basic gene Info.Gene symbolCAMKK2
Gene namecalcium/calmodulin-dependent protein kinase kinase 2, beta
CytomapUCSC genome browser: 12q24.2
Type of geneprotein-coding
DescriptionCAMKK beta proteincaM-KK 2caM-KK betacaM-kinase kinase 2caM-kinase kinase betacalcium/calmodulin-dependent protein kinase betacalcium/calmodulin-dependent protein kinase kinase 2
Modification date20141207
dbXrefs MIM : 615002
Ensembl : ENSG00000110931
HPRD : 06467
Vega : OTTHUMG00000169156
ProteinUniProt: Q96RR4
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_CAMKK2
BioGPS: 10645
PathwayNCI Pathway Interaction Database: CAMKK2
Pathway Commons: CAMKK2
ContextiHOP: CAMKK2
ligand binding site mutation search in PubMed: CAMKK2
UCL Cancer Institute: CAMKK2
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0006468protein phosphorylation11395482
GO:0046777protein autophosphorylation11395482

Ligand binding site mutations for CAMKK2

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for CAMKK2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for CAMKK2 from PDB

Differential gene expression and gene-gene network for CAMKK2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of CAMKK2 and the right PPI network was created from samples without mutations in the LBS of CAMKK2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for CAMKK2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for CAMKK2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of CAMKK2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of CAMKK2
Multiple alignments for Q96RR4 in multiple species
LBSAA sequence# speciesSpecies
A192DNTYYAMKVLS3Homo sapiens, Mus musculus, Rattus norvegicus
A192DKNLYALKVLD1Caenorhabditis elegans
D330HIKIADFGVSN3Homo sapiens, Mus musculus, Rattus norvegicus
D330QVKIADFGVSC1Caenorhabditis elegans
E268LYMVFELVNQG3Homo sapiens, Mus musculus, Rattus norvegicus
E268LYMVFEFVEKG1Caenorhabditis elegans
F267HLYMVFELVNQ3Homo sapiens, Mus musculus, Rattus norvegicus
F267YLYMVFEFVEK1Caenorhabditis elegans
G273ELVNQGPVMEV3Homo sapiens, Mus musculus, Rattus norvegicus
G273EFVEKGSILEI1Caenorhabditis elegans
K194TYYAMKVLSKK3Homo sapiens, Mus musculus, Rattus norvegicus
K194NLYALKVLDKM1Caenorhabditis elegans
L269YMVFELVNQGP3Homo sapiens, Mus musculus, Rattus norvegicus
L269YMVFEFVEKGS1Caenorhabditis elegans
L319KPSNLLVGEDG3Homo sapiens, Mus musculus, Rattus norvegicus
L319KPSNLLLSDIG1Caenorhabditis elegans
N271VFELVNQGPVM3Homo sapiens, Mus musculus, Rattus norvegicus
N271VFEFVEKGSIL1Caenorhabditis elegans
P274LVNQGPVMEVP3Homo sapiens, Mus musculus, Rattus norvegicus
P274FVEKGSILEIP1Caenorhabditis elegans
V179GSYGVVKLAYN3Homo sapiens, Mus musculus, Rattus norvegicus
V179GSYGIVKLAYN1Caenorhabditis elegans
V249DHPNVVKLVEV3Homo sapiens, Mus musculus, Rattus norvegicus
V249SHPNVVKLVEV1Caenorhabditis elegans
V270MVFELVNQGPV3Homo sapiens, Mus musculus, Rattus norvegicus
V270MVFEFVEKGSI1Caenorhabditis elegans

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas